author-photo

Angela L. Harris

University of Texas MD Anderson Cancer Center

12

Papers

96

Citations

Citation Trend

Filter By

Papers (8) Sort By

Journal Conference Others

Abstract 87: Asparagine synthetase (ASNS) expression predicts response to the GLS1 inhibitor IPN60090 in ovarian cancer through selective modulation of redox homeostasis

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Discovery of 6-[(3S,4S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 Inhibitor.

2021 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 1102: Integrated approach towards defining mechanism based combinations to guide clinical development of glutaminase inhibitors

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme.

2021 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (1)
Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties

2020 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (7)
Allosteric SHP2 inhibitor IACS-13909 overcomes EGFR-dependent and EGFR-independent resistance mechanisms towards osimertinib.

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (9)
Abstract C036: Discovery of IACS-13909, an allosteric SHP2 inhibitor that overcomes multiple mechanisms underlying osimertinib resistance

2019 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
Abstract LB-071: Discovery of an imidazopyridine series of potent human IDO1 inhibitors with robust target engagement in a preclinical tumor model

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)